Monkey Pox Vaccines – RobertW.MaloneMD 8/10/22


Significant side effects, and not the only option.

The Food and Drug Administration has already licensed two vaccines for monkeypox. Both were licensed a while ago, not in conjunction with this outbreak. The ACAM2000 and JYNNEOS vaccines are effective in combating smallpox, according to the FDA.

  • JYNNEOS (also known as Imvamune or Imvanex) is licensed (or approved) by the U.S. Food and Drug Administration (FDA) for the prevention of Monkeypox virus infection, and
  • ACAM2000 is licensed (or approved) by FDA for use against Smallpox and made available for use against Monkeypox under an Expanded Access Investigational New Drug application.

For a summary of the recent White House press conference on Monkey Pox vaccines, please see the recent Epoch Times article: “FDA Grants Emergency Use Authorization to Stretch Monkeypox Vaccine to Meet Demand

You can find a link to the recent amazingly bad press conference from the newly formed US Government White House Monkeypox Response Team here. After watching, I was left wondering if Bob Redfield is suffering neurological speech effects from COVID (or the mRNA vaccines).

This isn’t the first time that there there has been an outbreak of Monkey pox in the USA.

But it was NOT in the context of this outbreak, that the current smallpox vaccines were tested and licensed against monkeypox. Nope – it took 20 years after this outbreak for the FDA to get around to licensure of the small pox vaccines for monkeypox. These vaccines were licensed in 2019. What a strange coincidence – that this happened two years before the current outbreak!

According to the U.S. Centers for Disease Control, there is not yet any data available on the effectiveness of either vaccine in the current outbreak of monkeypox. But there is older data available from animal studies, clinical trials and studies in Africa.

Note: there have been no randomized clinical trials done, but lots of immunobridging type studies and an “in the field” trial by fire testing for post-exposure prophylaxis, or PEP of health care workers in Africa. Just like repurposed drugs and multi-drug, multi-stage treatments for COVID, there are studies that suggest efficacy. Which in this case, was plenty for the FDA to grant FULL licensure….

Read More…